CN101428094B - 一种药物组合物在制备改善脑微循环障碍药物中的应用 - Google Patents
一种药物组合物在制备改善脑微循环障碍药物中的应用 Download PDFInfo
- Publication number
- CN101428094B CN101428094B CN2007101500739A CN200710150073A CN101428094B CN 101428094 B CN101428094 B CN 101428094B CN 2007101500739 A CN2007101500739 A CN 2007101500739A CN 200710150073 A CN200710150073 A CN 200710150073A CN 101428094 B CN101428094 B CN 101428094B
- Authority
- CN
- China
- Prior art keywords
- ischemia
- reperfusion
- keli
- group
- thin vein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims description 9
- 230000004089 microcirculation Effects 0.000 title abstract description 27
- 210000004556 brain Anatomy 0.000 title description 49
- 208000028867 ischemia Diseases 0.000 claims abstract description 154
- 210000003462 vein Anatomy 0.000 claims abstract description 83
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 102000009027 Albumins Human genes 0.000 claims description 23
- 108010088751 Albumins Proteins 0.000 claims description 23
- 241000217407 Margaritifera Species 0.000 claims description 9
- 241000218176 Corydalis Species 0.000 claims description 7
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 2
- 244000179560 Prunella vulgaris Species 0.000 claims description 2
- 241000405414 Rehmannia Species 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 241000699684 Meriones unguiculatus Species 0.000 abstract description 60
- 210000004204 blood vessel Anatomy 0.000 abstract description 45
- 150000002978 peroxides Chemical class 0.000 abstract description 27
- 210000004369 blood Anatomy 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 16
- 230000002490 cerebral effect Effects 0.000 abstract description 15
- 230000003727 cerebral blood flow Effects 0.000 abstract description 14
- 230000008859 change Effects 0.000 abstract description 11
- 230000002146 bilateral effect Effects 0.000 abstract description 8
- 210000001715 carotid artery Anatomy 0.000 abstract description 7
- 230000000007 visual effect Effects 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 4
- 230000008728 vascular permeability Effects 0.000 abstract description 4
- 230000004064 dysfunction Effects 0.000 abstract 2
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 49
- 241000700159 Rattus Species 0.000 description 32
- 210000000265 leukocyte Anatomy 0.000 description 26
- 230000010412 perfusion Effects 0.000 description 23
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 22
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 241000699694 Gerbillinae Species 0.000 description 17
- 210000003038 endothelium Anatomy 0.000 description 15
- 210000003556 vascular endothelial cell Anatomy 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 102000007562 Serum Albumin Human genes 0.000 description 13
- 108010071390 Serum Albumin Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 210000003710 cerebral cortex Anatomy 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000007405 data analysis Methods 0.000 description 9
- 238000000556 factor analysis Methods 0.000 description 9
- 238000010149 post-hoc-test Methods 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 238000010998 test method Methods 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 6
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000001000 micrograph Methods 0.000 description 6
- -1 oxygen anion Chemical class 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 208000010248 Cerebrovascular Trauma Diseases 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 206010030124 Oedema peripheral Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 210000003191 femoral vein Anatomy 0.000 description 4
- 239000000834 fixative Substances 0.000 description 4
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000001202 rhombencephalon Anatomy 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000010926 vascular brain injury Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008081 blood perfusion Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- ZAUYNCUCMJDAHW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;hydrogen peroxide;molecular iodine Chemical compound OO.II.C=CN1CCCC1=O ZAUYNCUCMJDAHW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102100038591 Endothelial cell-selective adhesion molecule Human genes 0.000 description 1
- 101000799852 Equus asinus Alpha-1B-glycoprotein Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000882622 Homo sapiens Endothelial cell-selective adhesion molecule Proteins 0.000 description 1
- 101001001645 Homo sapiens Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010021699 I-kappa B Proteins Proteins 0.000 description 1
- 102000008379 I-kappa B Proteins Human genes 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 102100036119 Serine/threonine-protein kinase pim-3 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 238000006993 Weiss annulation reaction Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- IYPRWQPJYRBHIS-UHFFFAOYSA-N acetic acid;uranium Chemical compound [U].CC(O)=O IYPRWQPJYRBHIS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000743 anti-peroxide Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000004298 cerebral vein Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HDAFVOZRAUFNQH-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;perchloric acid Chemical compound [O-]Cl(=O)(=O)=O.C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC HDAFVOZRAUFNQH-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000002210 supercritical carbon dioxide drying Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101500739A CN101428094B (zh) | 2007-11-06 | 2007-11-06 | 一种药物组合物在制备改善脑微循环障碍药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101500739A CN101428094B (zh) | 2007-11-06 | 2007-11-06 | 一种药物组合物在制备改善脑微循环障碍药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101428094A CN101428094A (zh) | 2009-05-13 |
CN101428094B true CN101428094B (zh) | 2012-05-09 |
Family
ID=40643863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101500739A Active CN101428094B (zh) | 2007-11-06 | 2007-11-06 | 一种药物组合物在制备改善脑微循环障碍药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101428094B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102998375B (zh) * | 2011-09-13 | 2016-04-20 | 天士力制药集团股份有限公司 | 一种同时检测养血清脑颗粒中阿魏酸与芍药苷含量的方法 |
CN104435306A (zh) * | 2013-09-22 | 2015-03-25 | 天士力制药集团股份有限公司 | 养血清脑制剂在制备治疗阿尔茨海默症的药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1073874A (zh) * | 1992-11-14 | 1993-07-07 | 中国人民解放军第二五四医院 | 活血清脑冲剂 |
-
2007
- 2007-11-06 CN CN2007101500739A patent/CN101428094B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1073874A (zh) * | 1992-11-14 | 1993-07-07 | 中国人民解放军第二五四医院 | 活血清脑冲剂 |
Non-Patent Citations (5)
Title |
---|
吴迺峰 等.养血清脑颗粒剂的药效学研究.《解放军药学学报》.1997,(第3期),67. * |
张硕峰 等.养血清脑颗粒的镇痛作用及对脑组织血流量的影响.《中国实验方剂学杂志》.2007,第13卷(第1期),44-48. * |
李建华 等.养血清脑颗粒对蒙古沙鼠全脑缺血再灌注后的神经保护作用.《解剖学报》.2007,第38卷(第4期),419-423. * |
王中琳.养血清脑颗粒对MCAO模型大鼠神经功能保护机制研究.《辽宁中医杂志》.2002,第29卷(第12期),704-706. * |
蔡定芳 等.养血清脑颗粒治疗慢性脑供血不足实验研究.《中华老年医学杂志》.2005,第24卷(第3期),223-224. * |
Also Published As
Publication number | Publication date |
---|---|
CN101428094A (zh) | 2009-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ghersi-Egea et al. | Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat | |
JP7082041B2 (ja) | 薬剤送達装置および生物活性薬剤 | |
JP6929829B2 (ja) | 薬剤送達装置 | |
CN103442677A (zh) | 用于药物的经皮递送和全身性递送的纳米粒子 | |
JP2003506476A (ja) | 親水性治療剤の増強された吸収のための組成物および方法 | |
CN1997383B (zh) | 含水母发光蛋白的组合物及使用它的方法 | |
US20170087208A1 (en) | Pharmaceutical composition for anti-vascular diseases and anti-tumor and use thereof | |
CN107096013A (zh) | 鲑鱼降钙素可溶性微针贴片及其制备方法 | |
CN101347422B (zh) | 丹酚酸a在预防和\或治疗糖尿病及并发症中的应用 | |
CN101428094B (zh) | 一种药物组合物在制备改善脑微循环障碍药物中的应用 | |
Cocoș et al. | Challenges in Optimizing Nanoplatforms Used for Local and Systemic Delivery in the Oral Cavity | |
CN101548966A (zh) | 丹参丹酚酸a的用途 | |
Wang et al. | B16 membrane-coated vesicles for combined photodynamic therapy and immunotherapy shift immune microenvironment of melanoma | |
CN102000264B (zh) | 治疗更年期综合症的组合物的检测方法 | |
Abd El-Haleem et al. | Bone marrow–derived mesenchymal stem cells ameliorate parotid injury in ovariectomized rats | |
CN113056268A (zh) | 纤溶酶原激活物抑制剂1(pai-1)抑制剂和其用途 | |
CN110123854A (zh) | 一种基于北柴胡组分的抗炎活性药物组合物及其应用 | |
CN101530498A (zh) | 养血清脑颗粒对脑微循环障碍的改善作用 | |
Yoon et al. | Tracking adiponectin biodistribution via fluorescence molecular tomography indicates increased vascular permeability after streptozotocin-induced diabetes | |
CN109498617A (zh) | 藁本内酯在制备防治骨质疏松症药品中的应用 | |
Junqueira et al. | Permeation efficacy of a transdermal vehicle with steroidal hormones and nonsteroidal anti-inflammatory agents as model drugs | |
Ahuja et al. | Formulation and evaluation of diclofenac sodium gel by using natural polymer | |
CN101569608A (zh) | 一种降钙素的口服固体脂质纳米粒制剂及其制备方法 | |
CN101428093A (zh) | 一种药物组合物在制备抑制白蛋白外漏药物中的应用 | |
CN101428091A (zh) | 一种药物在制备抑制过氧化物的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |